Kenvue Inc. $KVUE Shares Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 156.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 63,620 shares of the company’s stock after acquiring an additional 38,821 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Kenvue were worth $1,097,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of KVUE. Vanguard Group Inc. lifted its holdings in Kenvue by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after purchasing an additional 1,604,040 shares during the period. American Century Companies Inc. raised its position in Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after acquiring an additional 6,781,640 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Kenvue by 13.5% in the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock worth $375,377,000 after acquiring an additional 2,747,952 shares in the last quarter. Van ECK Associates Corp raised its holdings in Kenvue by 101.3% during the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after buying an additional 9,240,434 shares during the period. Finally, Amundi raised its holdings in Kenvue by 21.6% during the 3rd quarter. Amundi now owns 17,645,761 shares of the company’s stock worth $277,012,000 after buying an additional 3,135,871 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on KVUE. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Barclays decreased their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Canaccord Genuity Group upped their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $23.00 to $18.00 in a report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average target price of $19.33.

Insider Transactions at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.59% of the stock is currently owned by corporate insiders.

Kenvue Stock Performance

Kenvue stock opened at $17.22 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.68. The stock has a fifty day moving average price of $17.52 and a two-hundred day moving average price of $17.30. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $24.35. The firm has a market capitalization of $33.05 billion, a P/E ratio of 20.25, a P/E/G ratio of 1.33 and a beta of 0.55.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.24 earnings per share. As a group, analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date is Wednesday, May 13th. Kenvue’s dividend payout ratio is presently 97.65%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.